CV Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue declined 7% sequentially to $3 million, with gross margin steady at 48.6% and operating expenses down 7.9%. Positive operating cash flow was achieved, and new product launches and regulatory developments are expected to support future growth.
-
Revenue declined 11% year-over-year to $3.2 million, but gross margin improved to 48.9% and operating expenses fell 13%. Adjusted EBITDA loss narrowed to $0.1 million, and positive operating cash flow was achieved. Regulatory and market headwinds persist.
Fiscal Year 2025
-
Revenue declined to $13.8M in 2025, but gross margin rose to 49% and cost reductions drove positive Q4 adjusted EBITDA. New product launches, acquisitions, and regulatory changes position the company for growth and improved cash flow in 2026.
-
Q3 2025 revenue declined 16% year-over-year to $3.3 million, with gross margin improving to 48.5%. Regulatory uncertainty and out-of-stock issues impacted sales, but cost controls and acquisition integration position the company for positive cash flow and growth in 2026.
-
Q2 2025 saw flat sequential revenue at $3.6M, a record 50.9% gross margin, and first positive adjusted EBITDA since 2019. Cost efficiency, new product launches, and M&A integration drove margin gains despite regulatory headwinds.
-
Q1 2025 saw revenue of $3.6M and a 46% gross margin, with cost savings and new product launches offsetting regulatory headwinds. In-sourcing manufacturing and M&A are expected to drive margin and cash flow improvements in the second half of 2025.
Fiscal Year 2024
-
Revenue for 2024 was $15.7 million, with improved gross margin and reduced operating expenses despite a challenging market. New product launches and acquisitions drove growth, while cost efficiency and cash management remain priorities.
-
Q3 2024 revenue held steady at $3.9M with a 46% gross margin, despite regulatory headwinds and a competitive market. Recent acquisitions and new product launches are expected to drive growth and positive cash flow in 2025.
-
Revenue and gross margin remained strong in Q2 2024, with improved profitability and reduced losses. Strategic acquisitions and cost efficiencies position the company for positive cash flow by year-end, despite ongoing regulatory and market challenges.